Safety and efficacy of edoxaban, an oral factor xa inhibitor, for thromboprophylaxis after total hip arthroplasty in Japan and Taiwan

T. Fuji*, C. J. Wang, S. Fujita, Y. Kawai, T. Kimura, S. Tachibana

*Corresponding author for this work

Research output: Contribution to journalJournal Article peer-review

57 Scopus citations

Abstract

Edoxaban, an oral direct factor Xa inhibitor, has proven antithrombotic efficacy. In a multicenter, phase II study, 264 total hip arthroplasty (THA) patients randomly received edoxaban 15 or 30 mg once daily or enoxaparin 2000. IU (20-mg) twice daily for 11-14 days. Thromboembolic event incidences were 3.8% (3/78), 2.8% (2/72), and 4.1% (3/74) for edoxaban 15-mg, 30-mg, and enoxaparin, respectively (P= 1.00). Edoxaban-induced prolongation of prothrombin time, international normalized ratio, and activated partial thromboplastin time were proportional to plasma edoxaban concentration. Major or clinically relevant non-major bleeding incidences were 2.2% (2/89), 1.2% (1/85), and 2.3% (2/87) for edoxaban 15-mg, 30-mg, and enoxaparin, respectively (P= 1.00). Once-daily edoxaban showed similar efficacy and safety to enoxaparin for prevention of thromboembolic events in patients undergoing THA.

Original languageEnglish
Pages (from-to)2439-2446
Number of pages8
JournalJournal of Arthroplasty
Volume29
Issue number12
DOIs
StatePublished - 01 12 2014

Bibliographical note

Publisher Copyright:
© 2014 The Authors.

Keywords

  • Edoxaban
  • Enoxaparin
  • Factor Xa inhibitor
  • Thromboembolic events
  • Total hip arthroplasty

Fingerprint

Dive into the research topics of 'Safety and efficacy of edoxaban, an oral factor xa inhibitor, for thromboprophylaxis after total hip arthroplasty in Japan and Taiwan'. Together they form a unique fingerprint.

Cite this